These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37183236)

  • 1. An Industry Survey on Unmet Needs in South Korea's New Drug Listing System.
    Kim S; Lee JY; Cho SH; Shin EJ; Kim M; Lee JH
    Ther Innov Regul Sci; 2023 Jul; 57(4):759-768. PubMed ID: 37183236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
    Yoo SL; Kim DJ; Lee SM; Kang WG; Kim SY; Lee JH; Suh DC
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of economic evaluation in the listing and pricing of pharmaceuticals].
    Lee TJ
    J Prev Med Public Health; 2008 Mar; 41(2):69-73. PubMed ID: 18385545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
    Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
    BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
    Cho E; Yoo SL; Kang Y; Lee JH
    Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.
    Lee JH
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33800373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
    Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
    Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.